N
ITCI

Natixis’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Natixis’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-549
Closed -$45.9K – 1220
2024
Q4 		$45.9K Sell
549
-178
-24% -$14.6K ﹤0.01% 890
2024
Q3 		$53.2K Sell
727
-435
-37% -$32.7K ﹤0.01% 782
2024
Q2 		$79.6K Sell
1,162
-2,571
-69% -$178K ﹤0.01% 751
2024
Q1 		$258K Buy
3,733
+2,329
+166% +$160K ﹤0.01% 691
2023
Q4 		$101K Sell
1,404
-74
-5% -$4.26K ﹤0.01% 774
2023
Q3 		$77K Sell
1,478
-14,403
-91% -$839K ﹤0.01% 803
2023
Q2 		$1.01M Buy
+15,881
New +$990K 0.01% 542

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Natixis's ITCI Position: Q1 2025 in Review

Natixis sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 549 shares — an estimated $45.9K sold.

Natixis first reported a position in ITCI in Q2 2023 and held it in 7 quarters. The position peaked at $1.01M in Q2 2023. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Natixis reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Natixis sold 549 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $45.9K.
  • Natixis first reported a position in Intra-Cellular Therapies Inc. in Q2 2023 and held it in 7 quarters.
  • Natixis's Intra-Cellular Therapies Inc. position peaked at $1.01M in Q2 2023.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Natixis's 13F filing for Q1 2025, filed 14 May 2025.